Companion Diagnostics Patent Landscape Analysis Report 2026 Edition

Companion Diagnostics Market Size, Growth Trends, and Industry Outlook

The market growth is driven by the Rising pharmaceutical drug development activity requiring regulatory-compliant biomarker tests, increasing co-development of targeted therapies and associated diagnostic tests, and expanding precision oncology protocols in major healthcare markets. The FDA has approved more than 90 companion diagnostic tests as of 2024, the majority linked to oncology indications, signalling the scale and regulatory precedent of the CDx market.

North America holds the leading position in the companion diagnostics market, supported by the highest volume of FDA companion diagnostic approvals, strong oncology drug pipeline activity, and broad reimbursement coverage for biomarker-guided oncology testing. Europe is the second largest market. Asia Pacific, particularly Japan and China, is emerging as a significant growth region, driven by domestic drug development pipelines and expanding NGS diagnostic infrastructure.

The commercial structure of companion diagnostics is distinguished by the prevalence of co-development agreements between diagnostics companies and pharmaceutical manufacturers. These partnerships typically involve joint regulatory submissions, commercial exclusivity for the associated assay, and revenue-sharing structures tied to drug sales volumes, creating durable commercial relationships and demand stability linked to pharmaceutical franchise performance.

Read more about this report - Request a Free Sample

Companion Diagnostics Patent Filing Trends and Innovation Activity

Patent filing activity within the companion diagnostics landscape reflects two distinct innovation drivers: platform-level diagnostics technology development and biomarker-specific assay development tied directly to pharmaceutical pipeline activity. Both streams have contributed to filing growth, with NGS-based companion assay technologies and liquid biopsy-based CDx platforms representing the most active recent filing categories.

Approximately 9,500+ patent families were identified across the companion diagnostics landscape during the analysis period. The period from 2020 to 2024 produced the highest annual filing volumes, coinciding with a wave of targeted therapy approvals across oncology and the rapid adoption of NGS-based profiling as a standard component of oncology CDx testing. Patent grants reached approximately 1,200+ in 2025.

The alignment between rising market demand and expanding patent activity reflects concentrated innovation investment directed at companion diagnostics platforms, particularly across commercially validated applications and high-growth emerging segments.

Scope of the Companion Diagnostics Patent Landscape Analysis Report

This report analyses patent activity and market trends associated with companion diagnostics technologies across major global jurisdictions and precision medicine markets. The scope includes FDA-approved and CE-IVD CDx assay technologies, NGS-based tumour profiling platforms, PCR and IHC-based companion assays, liquid biopsy companion diagnostics, and bioinformatics approaches applied in companion diagnostic development.

The analysis covers patent activity from dedicated diagnostics companies, integrated pharmaceutical and diagnostics groups, technology platform providers, academic research institutions, and emerging startups working on next-generation companion diagnostic platforms across oncology and other therapeutic areas.

The analysis includes patent activity from established diagnostics companies, instrument manufacturers, academic and research institutions, pharmaceutical companies, and emerging startups developing next-generation companion diagnostics technologies.

Global Companion Diagnostics Patent Landscape Analysis

Companion Diagnostics Patent Filing Trend Analysis

The report evaluates the historical evolution of patent filings associated with companion diagnostics technologies, identifying periods of accelerated innovation activity, shifts in competitive positioning, and emerging technology focus areas. Filing patterns are analysed to assess innovation momentum, market maturity signals, and long-term strategic direction.

Patent filings in companion diagnostics demonstrate a long-term upward trajectory with notable acceleration in the most recent filing cohort, driven by commercial investment cycles, regulatory milestone activity, and increasing competitive pressure among both established companies and dedicated innovators.

Leading Companies and Assignee Analysis in the Companion Diagnostics Patent Landscape

Geographic Analysis of Companion Diagnostics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States accounts for the largest share of companion diagnostics patent families, driven by the concentration of both pharmaceutical drug development and regulatory approval activity. European Patent Office filings are significant. Japan maintains a meaningful filing base, and China has demonstrated rising filing volumes in recent years linked to domestic oncology drug and diagnostic co-development programmes.

Read more about this report - Request a Free Sample

Companion Diagnostics Technology Segmentation and Innovation Areas

The patent landscape is segmented based on relevant technology categories associated with companion diagnostics. Key technology segments include:

• NGS-based tumour profiling and companion assays
• PCR-based biomarker detection and quantification
• Immunohistochemistry and protein expression platforms
• Liquid biopsy companion diagnostic methods
• AI-assisted biomarker stratification algorithms

Among these, NGS-based tumour profiling and companion assay technologies account for the largest and fastest-growing share of recent patent filings in the companion diagnostics landscape.

Competitive Landscape and Emerging Trends in the Companion Diagnostics Market

The companion diagnostics market remains highly competitive, characterised by increasing patent filings, strategic collaborations, licensing agreements, and technology partnerships. The report evaluates the competitive environment within the CDx ecosystem by assessing innovation activity, patent concentration, and strategic positioning of major stakeholders across oncology and other precision medicine therapeutic areas.

Companies are focusing on:

• Product differentiation
• AI and automation integration
• Workflow optimisation
• Precision enhancement
• Clinical efficiency improvement
• Manufacturing scalability
• Geographic expansion

Emerging innovation themes include RNA expression profiling CDx, multi-biomarker panel NGS assays, tumour mutational burden quantification, microsatellite instability detection, and multi-omic CDx approaches integrating genomic, transcriptomic, and proteomic data for patient stratification.

Strategic Insights from the Companion Diagnostics Patent Landscape

The evolving companion diagnostics landscape reflects increasing convergence between diagnostic technology, artificial intelligence, and clinical medicine. Patent filing trends, technology development, and competitive positioning indicate emerging opportunities for product development, strategic collaboration, licensing activity, and geographic expansion.

Technology segments demonstrating strong patent growth and increasing clinical adoption represent strategic opportunities for long-term investment. The report provides actionable intelligence to support:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Companion Diagnostics Patent Landscape Analysis

The companion diagnostics patent landscape analysis is developed through structured patent research incorporating CDx-specific terminology, biomarker names, therapeutic target identifiers, assay platform classifications, and CPC classification codes relevant to in vitro diagnostics and molecular pathology technologies.

Patent records are screened, refined, categorised, and consolidated to ensure relevance to the defined scope of companion diagnostics technologies. The analysis includes patent family standardisation, assignee mapping, technology clustering, and trend evaluation.

The market analysis is supported through secondary research, industry publications, company disclosures, healthcare databases, regulatory information, investment analysis, and market modelling approaches relevant to the companion diagnostics ecosystem.

Related Reports

Companion Diagnostics Market

Precision Oncology Market

Next Generation Sequencing Market